Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 1/20 | 0.50 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.50 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.50 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.50 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.50 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1118720 | 0.97 | PRKAB2 (0.51) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1118770 | 0.97 | PRKAB2 (0.51) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1118744 | 0.92 | PRKAB2 (0.49) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1118976 | 0.91 | PRKAB2 (0.56) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1118952 | 0.90 | PRKAG1 (0.64) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1191114 | 0.90 | PRKAB2 (0.46) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1190021 | 0.89 | PRKAB2 (0.47) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1118963 | 0.89 | PRKAB2 (0.46) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1118961 | 0.88 | PRKAB2 (0.47) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1191531 | 0.88 | PRKAB2 (0.54) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034505-A1 | THIENOPYRIDONE DERIVATIVES AS AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS | MERCK PATENT GESELLSCHAFT (DE) | 2011-02-10 | — | — | US | claimed |
| EP-2262500-A1 | THIENOPYRIDONE DERIVATIVES AS AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS | Merck Patent GmbH (DE) | 2010-12-22 | — | — | EP | claimed |
| WO-2009124636-A1 | THIENOPYRIDONE DERIVATIVES AS AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-10-15 | — | — | WO | claimed |
| US-8563729-B2 | Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators | MERCK PATENT GMBH (DE) | 2013-10-22 | — | — | US | disclosed |
| US-20110034505-A1 | THIENOPYRIDONE DERIVATIVES AS AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS | MERCK PATENT GESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| EP-2262500-A1 | THIENOPYRIDONE DERIVATIVES AS AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS | Merck Patent GmbH (DE) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009124636-A1 | THIENOPYRIDONE DERIVATIVES AS AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034505-A1 | THIENOPYRIDONE DERIVATIVES AS AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS | PRKAB1, PRKAG1, PRKAG3 | PRKAB2 4/4885PRKAG1 2/4885PRKAA2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.